Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.
about
Identification of a SART-1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytesBinding of a SART3 tumor-rejection antigen to a pre-mRNA splicing factor RNPS1: a possible regulation of splicing by a complex formationATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction.IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cellsCancer immunotherapy: moving beyond current vaccinesTherapeutic cancer vaccines: using unique antigensTranslation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineageThymic selection generates a large T cell pool recognizing a self-peptide in humansCancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytesCytotoxic T cell immunity against telomerase reverse transcriptase in humansCancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanomaVaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanomaDiversity and recognition efficiency of T cell responses to cancerForecasting the cytokine storm following systemic interleukin (IL)-2 administrationA balanced review of the status T cell-based therapy against cancerPhase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancerGene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administrationT-cell clonotypes in cancerTumor-associated antigens identified by mRNA expression profiling as tumor rejection epitopesT cell avidity and tumor recognition: implications and therapeutic strategies.Use of recombinant lentivirus pseudotyped with vesicular stomatitis virus glycoprotein G for efficient generation of human anti-cancer chimeric T cells by transduction of human peripheral blood lymphocytes in vitro.Therapeutic cancer vaccines: past, present, and futureCancer vaccines and T cell therapyOptimal management of metastatic melanoma: current strategies and future directionsCancer therapy using a self-replicating RNA vaccineClass I major histocompatibility complex anchor substitutions alter the conformation of T cell receptor contactsCa2+ release from the endoplasmic reticulum of NY-ESO-1-specific T cells is modulated by the affinity of TCR and by the use of the CD8 coreceptor.Structures of MART-126/27–35 Peptide/HLA-A2 Complexes Reveal a Remarkable Disconnect between Antigen Structural Homology and T Cell RecognitionT-cell Receptor-optimized Peptide Skewing of the T-cell Repertoire Can Enhance Antigen TargetingStructural and Functional Correlates of Enhanced Antiviral Immunity Generated by Heteroclitic CD8 T Cell EpitopesTumor cell lysates as immunogenic sources for cancer vaccine designHarnessing the Microbiome to Enhance Cancer ImmunotherapyExpression of tumor-rejection antigens in gynecologic cancersMouse homologue of the human SART3 gene encoding tumor-rejection antigenCytokines required for induction of histocompatibility leukocyte antigen-class I-restricted and tumor-specific cytotoxic T lymphocytes by a SART1-derived peptidePreferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic methods for hematological malignanciesExpression of tumor rejection antigens in colorectal carcinomasQuantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemiaCleavage and polyadenylation specificity factor (CPSF)-derived peptides can induce HLA-A2-restricted and tumor-specific CTLs in the majority of gastrointestinal cancer patientsIdentification of secernin 1 as a novel immunotherapy target for gastric cancer using the expression profiles of cDNA microarray
P2860
Q22009435-F08A39C4-744B-4B1E-84EA-1274D64ADAFBQ24291494-CC5C716B-76C9-440B-9EFB-6F0A9493B82AQ24531314-D5A7D006-8A57-4EDE-8551-5BE6A3E183FCQ24546362-7376A0B3-F3B4-430D-9417-2DF1CB5E1A64Q24548229-D30242E0-3921-4A00-8210-7A13454C4DC6Q24563772-440E73BD-AEB3-4C52-8CE1-894BFE4FF866Q24646800-824991D5-78EE-422A-85A0-6B8FE50D7845Q24675080-50F50371-70A6-4BC1-85C8-5785BC567748Q24676216-1C3C1FB7-9D91-40A2-838D-803DD922E3CDQ24676613-626B7985-5D22-4500-86CF-370C60F125DEQ24679736-45C34F84-504E-4876-93D4-3D967B00AE87Q24684238-C1742B9E-8997-4E50-8C03-FB00E2427FA5Q24796652-D9C98CD6-9B65-4198-B4F6-4E38FBEF948BQ24796741-11BC3888-14DB-457A-93A2-5EDFC904A75FQ24800636-3C681198-17CB-42A2-A09F-50EB795827E2Q24801232-D1E8C707-5903-45C8-99B2-4BCF8744000AQ24802736-A8B58055-A4C7-4DEC-9601-83874DBC0551Q24803891-DE641B28-B750-4A96-AF3E-7E0AF84AABDBQ24806913-7074D2A9-BA45-49DE-B543-60E8B3DABA26Q24815775-54949D59-941B-43DD-B76B-97061C3C4765Q25257888-32EF72D0-F6D5-422F-B545-B1F845944354Q26863283-6BC02DBA-A01E-4B5B-A9EF-6AE1FBE0E1F6Q26995638-63D9122B-099D-4A32-BB38-CDB8A0A47B25Q26997338-82BF6290-E568-4F63-9A9C-364A20433BC9Q27481056-17B23986-5F82-4038-8B1F-61B3D7B34B25Q27631018-169A6D49-E2A5-4EF0-ADA6-303348C17685Q27646628-68B1EA92-4227-4E09-BFFA-52ACEDA9A757Q27647534-B1BACAC1-4E98-4F1D-AAA6-1CF67FF87F3AQ27672418-8EF58520-5C66-4C62-83C9-192D2DBDBDACQ27683638-47F6585D-9AAF-4B8C-A492-20C6079483BDQ28083469-F6451D11-3448-49E5-8E42-9FAAE2B5C923Q28088598-ABCD7847-706E-4FFF-8471-41451EE7B1E9Q28138549-E052089A-54B7-4C11-8D5D-3BCFB8AF0914Q28141597-B30F1124-94C3-4A82-9048-CEAA140FE42CQ28146219-9FC77886-C6CD-41B3-AB1E-37F73600E8E5Q28190215-26282355-806C-4047-959A-515F6FC6BCE5Q28211063-053FFEF2-3450-4B53-B458-390C7A8E1F05Q28212054-A22D97DA-5055-47EF-B2A5-0A7D4BC79362Q28216625-B588399E-9CEB-46AB-BAE7-F5FCB469A834Q28235811-35B8CB12-F697-4F6E-8DED-CEF56FC29FCE
P2860
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Immunologic and therapeutic ev ...... ents with metastatic melanoma.
@ast
Immunologic and therapeutic ev ...... ents with metastatic melanoma.
@en
type
label
Immunologic and therapeutic ev ...... ents with metastatic melanoma.
@ast
Immunologic and therapeutic ev ...... ents with metastatic melanoma.
@en
prefLabel
Immunologic and therapeutic ev ...... ents with metastatic melanoma.
@ast
Immunologic and therapeutic ev ...... ents with metastatic melanoma.
@en
P2093
P2860
P356
P1433
P1476
Immunologic and therapeutic ev ...... ents with metastatic melanoma.
@en
P2093
D J Schwartzentruber
F M Marincola
J H Einhorn
J R Wunderlich
M E Dudley
M R Parkhurst
N P Restifo
P2860
P2888
P304
P356
10.1038/NM0398-321
P407
P577
1998-03-01T00:00:00Z
P5875
P6179
1042802949